SynthesisPloS one2014
Association of HLA-DP/DQ and STAT4 polymorphisms with HBV infection outcomes and a mini meta-analysis.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Association ofBioscience reports · 2019Pooled it
- Relationship between HLA-DQ Gene Polymorphism and Hepatitis B Virus Infection.BioMed research international · 2017Pooled it
- Quantitative assessment of common genetic variations in HLA-DP with hepatitis B virus infection, clearance and hepatocellular carcinoma development.Scientific reports · 2015Pooled it
- Genetic variants in the 6p21.3 region influence hepatitis B virus clearance and chronic hepatitis B risk in the Han Chinese population.Liver research (Beijing, China) · 2024Article
- Assessment of STAT4 Variants and Risk of Hepatocellular Carcinoma in Latin Americans and Europeans.Cancers · 2023Article
- Possible association ofGlobal health & medicine · 2022Article
- Variation and expression of HLA-DPB1 gene in HBV infection.Immunogenetics · 2021Article
- Interferon and Hepatitis B: Current and Future Perspectives.Frontiers in immunology · 2021Review
- The Weight of HLA-DPA1 rs3077 Single Nucleotide Polymorphism in Prostate Cancer, a Multicenter Study.Prostate cancer · 2021Article
- STAT4: an immunoregulator contributing to diverse human diseases.International journal of biological sciences · 2020Review
- Host Genetic Determinants of Hepatitis B Virus Infection.Frontiers in genetics · 2019Review
- Host genetic factors affecting hepatitis B infection outcomes: Insights from genome-wide association studies.World journal of gastroenterology · 2018Review
- Multiple genetic variants associated with posttransplantation diabetes mellitus in Chinese Han populations.Journal of clinical laboratory analysis · 2018Article
- Article
- Systematic Review and Meta-Analysis on the Association between Polymorphisms in Genes of IL-12 Signaling Pathway and Hepatocellular Carcinoma Risk.Journal of Cancer · 2018Article
- Correlation of HLA-DP/DQ polymorphisms with transplant etiologies and prognosis in liver transplant recipients.Medicine · 2017Observational
- Genetic Polymorphisms of rs3077 and rs9277535 in HLA-DP associated with Systemic lupus erythematosus in a Chinese population.Scientific reports · 2017Article
- Current hepatitis B virus infection situation in Indonesia and its genetic diversity.World journal of gastroenterology · 2016Review
- Host Genetic Variants in HLA Loci Influence Risk for Hepatitis B Virus Infection in Children.Hepatitis monthly · 2016Article
- Clinicopathological significance of STAT4 in hepatocellular carcinoma and its effect on cell growth and apoptosis.OncoTargets and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThough HLA-DP/DQ is regarded to associate with HBV susceptibility and HBV natural clearance, its role in hepatocellular carcinoma (HCC) development is obscure. And the role of STAT4 in HBV susceptibility and clearance as well as HCC development is still contentious. Therefore, we conducted this study, aiming to clarify these obscure relationships.
methodsWe recruited 1312 Chinese Han subjects including healthy controls, HBV carriers and HCC patients in the experiment stage. The meta-analysis included 3467 HCC patients and 5821 HBV carriers to appraise the association with HCC development.
resultsConsistent with previous studies, HLA-DP/DQ associated with HBV susceptibility and HBV natural clearance (p<0.05). However, the experiment showed that HLA-DP rs3077, rs9277535 and rs7453920 did not associate with HCC development (dominant model, rs3077, OR = 0.86, 95%CI = 0.62-1.18; rs9277535, OR = 0.94, 95%CI = 0.68-1.30; rs7453920, OR = 0.75, 95%CI = 0.44-1.27). Meta-analysis again consolidated this conclusion (allele model, rs3077, OR = 0.94, 95%CI = 0.87-1.02; rs9277535, OR = 1.04, 95%CI = 0.97-1.11; rs7453920, OR = 0.89, 95%CI = 0.76-1.02). As for STAT4 rs7574865, we did not find any significant association with HBV susceptibility (OR = 0.91, 95%CI = 0.66-1.26) or HBV natural clearance (OR = 1.13, 95%CI = 0.86-1.49). Moreover, current data failed to acquire positive connection of rs7574865 with HCC development (experiment, OR = 0.86, 95%CI = 0.62-1.19; meta-analysis, OR = 0.87, 95%CI = 0.74-1.03), which may be due to the small sample size.
conclusionsHLA-DP/DQ polymorphisms (rs3077, rs9277535, rs7453920) did not associate with HCC development, but did correlate with HBV susceptibility and HBV natural clearance. STAT4 rs7574865 seemed not to correlate with HBV susceptibility or natural clearance. And it seemed rather ambiguous in its role on HCC development at present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.